Abstract
Cognitive impairment exists in Parkinson’s disease (PD) as a transitional state between cognitively intact and demented PD patients. It seems to be a risk factor for the development of dementia in PD, but the precise criteria and unfavorable cognitive profile of mild cognitive impairment in PD (MCI-PD) have not yet been established. The concept may turn to be different from that in Alzheimer’s disease since we search for those already diagnosed PD patients who are at risk of developing dementia. In addition, clinical variables specific for PD also play role. Importantly, MCI possesses a metabolic basis in PD. Various biomarkers particularly including neuropsychological testing and the brain imaging hold promise in identification of MCI-PD patients with unfavorable prognoses. Well-designed longitudinal studies in MCI-PD cohorts are needed to assess the sensitivity and specificity of the PD-MCI designation as far as dementia development is concerned.
Similar content being viewed by others
References
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study Group (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72:1121–1126
Aarsland D, Bronnick K, Williams-Gray C et al (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75:1062–1069
Alves G, Brønnick K, Aarsland D, et al. (2010) CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson’s Disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080–1086
Apostolova LG, Beyer M, Green AE et al (2010) Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord 25:687–688
Beyer MK, Janvin CC, Larsen JP, Aarsland D (2007) A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78:254–259
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain patology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–210
Braak H, Rub U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J Neurol Sci 248:255–258
Caviness JN, Driver-Dunckley E, Connor DJ et al (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22:1272–1277
Cools R (2006) Dopaminergic modulation of cognitive function implications for l-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev 30:1–23
Dubois B (2007) Is PD-MCI a useful concept? Mov Disord 22:1215–1216
Dubois B, Burn D, Goetz C et al (2007a) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324
Dubois B, Feldman HH, Jacova C et al (2007b) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746
Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementi associated with Parkinson’s disease. Mov Disord 22:1689–1707
Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 127:550–560
Hilker R, Thomas AV, Klein JC et al (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65:1716–1722
Hosokai Y, Nishio Y, Hirayama K et al (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24:854–862
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2007) Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage 34:714–723
Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D (2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:1470–1477
Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 50:140–148
Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R (1995) Neuropsychological characteristics of preclinical dementi in Parkinson’s disease. Neurology 45:1691–1696
Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson’s disease: a community based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 18:149–154
Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006) Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 21:1343–1349
Korczyn AD, Reichmann H (2006) Dementia with Lewy bodies. J Neurol Sci 248:3–8
Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24:1103–1110
Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106:257–270
Liepelt I, Reimold M, Maetzler W et al (2009) Cortical hypometabolism assessed by a metabolic ratio in Parkinson’s disease primarily reflects cognitive deterioration-[18F] FDG-PET. Mov Disord 24:1504–1511
Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819
Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64:178–183
Mamikonyan E, Moberg PJ, Siderowf A et al (2009) Mild cognitive impairment is common in Parkinson’s disease patients with normal mini-mental state examination (MMSE) scores. Parkinsonism Relat Disord 15:226–231
Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239–1245
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194
Petersen RC, Smith GE, Waring SC, Vnik RJ, Tantalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308
Piccirilli M, D’Alessandro P, Finali G, Piccinin GL, Agostini L (1989) Frontal lobe dysfunction in Parkinson’s disease: prognostic value for dementia? Eur Neurol 29:71–76
Shimada H, Hirano S, Shinotoh H et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278
Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology 75:1055–1061
Tomer R, Aharon-Peretz J, Tsitrinbaum Z (2007) Dopamine asymmetry interacts with medication to affect cognition in Parkinson’s disease. Neuropsychologia 45:357–367
Tröster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18:103–119
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798
Wolters E, Braak H (2006) Parkinson’s disease: promotor clinico-pathological correlations. J Neural Transm 70(Suppl):309–319
Acknowledgments
This work was supported by grant MSD 0021622404 from the Czech Ministry of Education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rektorova, I. Mild cognitive impairment exists in Parkinson’s disease. J Neural Transm 118, 1179–1183 (2011). https://doi.org/10.1007/s00702-011-0674-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-011-0674-x